Compare Amphastar Pharmaceuticals Inc (AMPH) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Flux Power Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.04 (market cap $868.62M), while Flux Power Holdings Inc trades at $0.6 (market cap $11.23M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 77.3× Flux Power Holdings Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FLUX | |
|---|---|---|
Market Cap | $868.62M | $11.23M |
Sector | Health | Utilities |
52-Week High | $30.81 | $6.66 |
52-Week Low | $16.87 | $0.51 |
Enterprise Value | $1.27B | $17.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.98, down 1.62% today, with a bullish technical signal supported by moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
The outlook is balanced with analyst consensus leaning Hold (66.67%) amid regulatory scrutiny and competitive pressures. Near-term catalysts include pipeline developments, but risks from FDA warnings and generic drug tariff uncertainties warrant caution. Cash flow trends improved with 2026 net cash flow projected at $36 million.
FLUX trades at $0.5702, up 8.82% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The company reported mixed quarterly results, missing EPS estimates in Q3 2025 and Q1 2026 while beating in Q4 2025. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 6 buy ratings. Recent developments include the upcoming Q4 2026 earnings call and the launch of SkyEMS 3.0 with AI-powered fleet insights.
FLUX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish sentiment from Wall Street contrasts with persistent losses and negative ROE/ROA. Key catalysts include execution on new product launches and path to profitability, while risks involve sustained cash burn and competitive pressure in clean energy storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
